Terms: = Thyroid cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Treatment
45 results:
1. The influence of thyroid hormone medication on intra-therapeutic half-life of
Happel C; Kranert WT; Bockisch B; Sabet A; Grünwald F; Groener D
Sci Rep; 2022 Aug; 12(1):13925. PubMed ID: 35978004
[TBL] [Abstract] [Full Text] [Related]
2. The continuum of care of anticancer treatment-induced hypothyroidism in patients with solid non-thyroid tumors: time for an intimate collaboration between oncologists and endocrinologists.
Deligiorgi MV; Trafalis DT
Expert Rev Clin Pharmacol; 2022 May; 15(5):531-549. PubMed ID: 35757870
[TBL] [Abstract] [Full Text] [Related]
3. Isovitexin potentiated the antitumor activity of cisplatin by inhibiting the glucose metabolism of lung cancer cells and reduced cisplatin-induced immunotoxicity in mice.
Chen RL; Wang Z; Huang P; Sun CH; Yu WY; Zhang HH; Yu CH; He JQ
Int Immunopharmacol; 2021 May; 94():107357. PubMed ID: 33715980
[TBL] [Abstract] [Full Text] [Related]
4. Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma.
Harvey RD; Carthon BC; Lewis C; Hossain MS; Zhang C; Chen Z; Harris WB; Alese OB; Shaib W; Bilen MA; Lawson DH; Wu C; Steuer CE; El-Rayes BF; Khuri FR; Lonial S; Waller EK; Ramalingam SS; Owonikoko TK
Br J Cancer; 2020 Oct; 123(8):1228-1234. PubMed ID: 32704173
[TBL] [Abstract] [Full Text] [Related]
5. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors.
Kurimoto C; Inaba H; Ariyasu H; Iwakura H; Ueda Y; Uraki S; Takeshima K; Furukawa Y; Morita S; Yamamoto Y; Yamashita S; Katsuda M; Hayata A; Akamatsu H; Jinnin M; Hara I; Yamaue H; Akamizu T
Cancer Sci; 2020 May; 111(5):1468-1477. PubMed ID: 32086984
[TBL] [Abstract] [Full Text] [Related]
6. thyroid dysfunctions secondary to cancer immunotherapy.
Chalan P; Di Dalmazi G; Pani F; De Remigis A; Corsello A; Caturegli P
J Endocrinol Invest; 2018 Jun; 41(6):625-638. PubMed ID: 29238906
[TBL] [Abstract] [Full Text] [Related]
7. Genistein improves thyroid function in Hashimoto's thyroiditis patients through regulating Th1 cytokines.
Zhang K; Wang Y; Ma W; Hu Z; Zhao P
Immunobiology; 2017 Feb; 222(2):183-187. PubMed ID: 27729167
[TBL] [Abstract] [Full Text] [Related]
8. The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.
Martin del Campo SE; Levine KM; Mundy-Bosse BL; Grignol VP; Fairchild ET; Campbell AR; Trikha P; Mace TA; Paul BK; Jaime-Ramirez AC; Markowitz J; Kondadasula SV; Guenterberg KD; McClory S; Karpa VI; Pan X; Olencki TE; Monk JP; Mortazavi A; Tridandapani S; Lesinski GB; Byrd JC; Caligiuri MA; Shah MH; Carson WE
J Immunol; 2015 Sep; 195(5):1995-2005. PubMed ID: 26238487
[TBL] [Abstract] [Full Text] [Related]
9. Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma.
Gibney GT; Atkins MB
J Clin Oncol; 2015 Jun; 33(17):1873-7. PubMed ID: 25964248
[TBL] [Abstract] [Full Text] [Related]
10. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro.
Angell TE; Lechner MG; Jang JK; LoPresti JS; Epstein AL
Clin Cancer Res; 2014 Dec; 20(23):6034-44. PubMed ID: 25294906
[TBL] [Abstract] [Full Text] [Related]
11. Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies.
Vitale G; Lupoli G; Guarrasi R; Colao A; Dicitore A; Gaudenzi G; Misso G; Castellano M; Addeo R; Facchini G; Del Prete S; Caraglia M
J Clin Endocrinol Metab; 2013 Oct; 98(10):E1567-74. PubMed ID: 23884781
[TBL] [Abstract] [Full Text] [Related]
12. Effect of high-dose intravenous vitamin C on inflammation in cancer patients.
Mikirova N; Casciari J; Rogers A; Taylor P
J Transl Med; 2012 Sep; 10():189. PubMed ID: 22963460
[TBL] [Abstract] [Full Text] [Related]
13. Additive effects of ulinastatin and docetaxel on growth of breast cancer xenograft in nude mice and expression of PGE2, IL-10, and il-2 in primary breast cancer cells.
Zhong B; Shen H; Sun X; Wang H; Zhang Y; Sun Z
Cancer Biother Radiopharm; 2012 May; 27(4):252-8. PubMed ID: 22594905
[TBL] [Abstract] [Full Text] [Related]
14. Interleukin-4 downregulates CD127 expression and activity on human thymocytes and mature CD8+ T cells.
Crawley AM; Vranjkovic A; Young C; Angel JB
Eur J Immunol; 2010 May; 40(5):1396-407. PubMed ID: 20201040
[TBL] [Abstract] [Full Text] [Related]
15. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides.
Ghori F; Polder KD; Pinter-Brown LC; Hoff AO; Gagel RF; Sherman SI; Duvic M
J Clin Endocrinol Metab; 2006 Jun; 91(6):2205-8. PubMed ID: 16595600
[TBL] [Abstract] [Full Text] [Related]
16. Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2.
Chianese-Bullock KA; Woodson EM; Tao H; Boerner SA; Smolkin M; Grosh WW; Neese PY; Merrill P; Petroni GR; Slingluff CL
J Immunother; 2005; 28(4):412-9. PubMed ID: 16000961
[TBL] [Abstract] [Full Text] [Related]
17. A pilot study of combined suicide/cytokine gene therapy in two patients with end-stage anaplastic thyroid carcinoma.
Barzon L; Pacenti M; Taccaliti A; Franchin E; Bruglia M; Boscaro M; Palù G
J Clin Endocrinol Metab; 2005 May; 90(5):2831-4. PubMed ID: 15713704
[TBL] [Abstract] [Full Text] [Related]
18. Graves' disease after interleukin-2 therapy in a patient with human immunodeficiency virus infection.
Jimenez C; Moran SA; Sereti I; Wynne S; Yen PM; Falloon J; Davey RT; Sarlis NJ
Thyroid; 2004 Dec; 14(12):1097-102. PubMed ID: 15650365
[TBL] [Abstract] [Full Text] [Related]
19. Viral mediated gene therapy for the management of metastatic thyroid carcinoma.
DeGroot LJ; Zhang R
Curr Drug Targets Immune Endocr Metabol Disord; 2004 Sep; 4(3):235-44. PubMed ID: 15379725
[TBL] [Abstract] [Full Text] [Related]
20. Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients.
Sartore-Bianchi A; Soriani A; Mattioni R; Vaglio A; Buzio C; Porta C
Oncol Rep; 2004 Oct; 12(4):855-9. PubMed ID: 15375512
[TBL] [Abstract] [Full Text] [Related]
[Next]
